CDXS
Price
$2.42
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
218.45M
54 days until earnings call
TECH
Price
$54.41
Change
+$1.49 (+2.82%)
Updated
Sep 5 closing price
Capitalization
8.46B
59 days until earnings call
Interact to see
Advertisement

CDXS vs TECH

Header iconCDXS vs TECH Comparison
Open Charts CDXS vs TECHBanner chart's image
Codexis
Price$2.42
Change-$0.00 (-0.00%)
Volume$722.31K
Capitalization218.45M
Bio-Techne
Price$54.41
Change+$1.49 (+2.82%)
Volume$1.75M
Capitalization8.46B
CDXS vs TECH Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. TECH commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and TECH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CDXS: $2.42 vs. TECH: $54.41)
Brand notoriety: CDXS and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 65% vs. TECH: 83%
Market capitalization -- CDXS: $218.45M vs. TECH: $8.46B
CDXS [@Biotechnology] is valued at $218.45M. TECH’s [@Biotechnology] market capitalization is $8.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, TECH is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 5 bearish.
  • TECH’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, TECH is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а -11.36% price change this week, while TECH (@Biotechnology) price change was -0.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

CDXS is expected to report earnings on Oct 30, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($8.46B) has a higher market cap than CDXS($218M). TECH YTD gains are higher at: -24.135 vs. CDXS (-49.266). CDXS has less debt than TECH: CDXS (69M) vs TECH (423M).
CDXSTECHCDXS / TECH
Capitalization218M8.46B3%
EBITDA-52.78MN/A-
Gain YTD-49.266-24.135204%
P/E RatioN/A118.28-
Revenue57.2MN/A-
Total Cash66.3MN/A-
Total Debt69M423M16%
FUNDAMENTALS RATINGS
CDXS vs TECH: Fundamental Ratings
CDXS
TECH
OUTLOOK RATING
1..100
1454
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9980
PRICE GROWTH RATING
1..100
6462
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for CDXS (38) in the Chemicals Specialty industry. This means that TECH’s stock grew somewhat faster than CDXS’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that TECH’s stock grew similarly to CDXS’s over the last 12 months.

TECH's SMR Rating (80) in the Biotechnology industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that TECH’s stock grew similarly to CDXS’s over the last 12 months.

TECH's Price Growth Rating (62) in the Biotechnology industry is in the same range as CDXS (64) in the Chemicals Specialty industry. This means that TECH’s stock grew similarly to CDXS’s over the last 12 months.

TECH's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that TECH’s stock grew significantly faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSTECH
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 9 days ago
85%
Bullish Trend 25 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 5 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SAGP34.040.21
+0.61%
Strategas Global Policy Opp ETF
PPIE27.320.12
+0.43%
Putnam PanAgora ESG Intl Eq ETF
QHY46.530.10
+0.22%
WisdomTree US Hi Yld Corp Bd
SPAM32.00N/A
N/A
Themes Cybersecurity ETF
FFEB54.13-0.10
-0.19%
FT Vest US Equity Buffer ETF Feb

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
N/A
DNLI - CDXS
50%
Loosely correlated
+4.33%
PRAX - CDXS
49%
Loosely correlated
+1.65%
BEAM - CDXS
47%
Loosely correlated
+12.62%
CRSP - CDXS
47%
Loosely correlated
+4.02%
IPSC - CDXS
45%
Loosely correlated
+5.41%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with SYRE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
+2.82%
SYRE - TECH
48%
Loosely correlated
+0.06%
MRVI - TECH
46%
Loosely correlated
+6.36%
CDXS - TECH
45%
Loosely correlated
N/A
MRNA - TECH
45%
Loosely correlated
+3.54%
FTRE - TECH
44%
Loosely correlated
+10.66%
More